Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.

Kv1.3 potassium channels as a therapeutic target in multiple sclerosis

Rangaraju, Srikant, Chi, Victor, Pennington, Michael W, Chandy, K George · 2009 · Expert Opinion on Therapeutic Targets

Abstract

We discuss the potential use of inhibitors of Kv1.3 potassium channels in T lymphocytes as therapeutics for multiple sclerosis. Current treatment strategies target the immune system in a non-selective manner. The resulting general immunosuppression, toxic side-effects and increased risk of opportunistic infections create the need for more selective therapeutics. Autoreactive effector-memory T (T(EM)) cells, considered to be major mediators of autoimmunity, express large numbers of Kv1.3 channels. Selective blockers of Kv1.3 inhibit calcium signaling, cytokine production and proliferation of T(EM) cells in vitro, and T(EM) cell-motility in vivo. Kv1.3 blockers ameliorate disease in animal models of multiple sclerosis, rheumatoid arthritis, type 1 diabetes mellitus and contact dermatitis without compromising the protective immune response to acute infections. Kv1.3 blockers have a good safety profile in rodents and primates.

Overview

Integrity signals

Registry

Crossref · 10.1517/14728220903018957

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 154 references

Research works printed but not linked: 8

  1. Grissmer, 1988, A marker for lymphoproliferative diseases? J Immunol, 141, 1137
  2. Sallusto, 2000, Curr Top Microbiol Immunol, 251, 167
  3. Bohuslavizki, 1992, Gen Physiol Biophys, 11, 507
  4. Fdez-Freire, 2005, J Drugs Dermatol, 4, 374
  5. Arkett, 1994, Receptors Channels, 2, 281
  6. Manabe, 1998, Res Commun Mol Pathol Pharmacol, 99, 33
  7. Mathew, 2006, Trop Gastroenterol, 27, 87
  8. Viglietta, 2002, J Clin Invest, 109, 895, 10.1172/JCI0214114 · doi:10.1172/jci0214114 · Paper page

Cited by

See all 99

Metadata

Authors
Rangaraju, S., Chi, V., Pennington, M. W., & Chandy, K. G.
Affiliations
University of California, Irvine (US)
Venue
Expert Opinion on Therapeutic Targets
Published
2009-06-20
Volume
13
Issue
8
Pages
909-924
ISSN
  • 1472-8222 (ISSN-L)
  • 1744-7631
OpenAlex
W2014156502
Cited by
99
References
154
Citations by year
2026: 4 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 9 · 2015: 8 · 2014: 4 · 2013: 5 · 2012: 11
FWCI
4.16
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Therapeutic Targets (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Neurological Disorders and Stroke (NS-048252, R01NS048252)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords
Kv1.3 potassium channel, multiple sclerosis, T cells, effector memory T cells, autoimmunity, immunosuppression, T cell proliferation, T cell motility, calcium signaling, rheumatoid arthritis, type 1 diabetes, contact dermatitis, drug safety
MeSH terms
Animals, Humans, Multiple Sclerosis, T-Lymphocytes, Cytokines, Drug Delivery Systems, Potassium Channel Blockers, Cell Proliferation, Kv1.3 Potassium Channel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. https://app.cochat.ai/papers/10.1517/14728220903018957
The paper
Rangaraju, S., Chi, V., Pennington, M. W., & Chandy, K. G. (2009). Kv1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opinion on Therapeutic Targets. https://doi.org/10.1517/14728220903018957

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.